SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Fueled by reports of potential partnerships with tech giants like Apple and TSMC, Intel is experiencing a surge, with the community buzzing about a possible turnaround. Investors are closely watching for further developments and gauging the long-term potential, as many see this as the start of a significant uptrend. Some are locking in profits, while others are holding, anticipating even greater gains.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending following news of a significant AI hosting agreement with Fluidstack, backstopped by Google; however, the stock price reaction is negative due to concerns about a simultaneous announcement of a convertible note offering. Community discussions revolve around whether the Google backing validates the company's direction, or if dilution from the offering outweighs the positive news. Some traders believe that the dip is a buying opportunity, while others are concerned about the potential impact of dilution.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco's earnings are a major point of discussion, with investors closely monitoring membership trends and potential impacts from tariffs, as well as debate about whether the company is currently overvalued. The community is actively discussing the potential for a stock split and speculating on the direction the stock will take after the earnings release. Some traders are positioning themselves for a move based on technical indicators, while others are focused on consumer spending and the broader economic outlook.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid market volatility and discussions around a potential government shutdown impacting risk assets. Community members are debating dip-buying opportunities, key support levels, and potential for an 'Uptober' rally, while some point to institutional investments as a bullish signal. Others express concern over recent liquidations and potential for further downside.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors discuss potential acquisition rumors and await a new CEO announcement, with some community members speculating about a potential buyer. Bullish sentiment revolves around the company's role in the expanding AI market and anticipation of a short squeeze. Others express frustration with the stock's recent performance and concerns about management.

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SciSparc Ltd

Scisparc Ltd

SPRC is trending following news of a quantum computing initiative for AI drug discovery, sparking significant community interest. The stock's low float and a pending merger with AutoMax are also contributing to the heightened discussion and volatility. Some traders are pointing to a potential short squeeze due to high borrowing fees.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas Corp is trending following reports that the U.S. government may take an equity stake as part of loan renegotiations, fueling optimism about domestic lithium production. The community is discussing the potential for a short squeeze and comparing it to past events with companies like MP Materials, while highlighting the importance of lithium for national security and AI development. Some traders are cautious, pointing to potential dilution and technical indicators suggesting a possible pullback.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors discuss its recent price action and potential catalysts, including strong iPhone 17 demand and a possible investment in Intel. The community is debating whether the stock is overvalued and anticipating potential price movements, with some expecting a continued push towards new all-time highs. Additionally, there's speculation around potential AI/AR developments from Apple.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community members discuss recent price drops and debate the stock's future. Some traders speculate about potential support levels and future buying opportunities, while others express frustration over the recent performance despite positive developments in the weight loss drug market, including potential for Alzheimer's treatment.

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

PepGen Inc

PEPG is trending due to positive clinical trial results for its DM1 therapy, sparking significant after-hours activity and a price target increase; however, the company's announcement of a public offering to fund clinical programs is generating mixed sentiment, with community members debating the impact of potential dilution versus the promising trial data and short squeeze potential.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ardelyx Inc. (ARDX) jumped 16% higher on Tuesday morning after multiple brokerages upped their price targets on the stock following an upbeat second-quarter earnings report and management changes.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels. According to Stocktwits data, retail chatter around ARDX jumped 1738% over the past 24 hours, as of Tuesday morning.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_05_at_10_56_25_AM_png_178eba0feb.webp" alt="ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user heaped praises on the management.<stembedurl>https://stocktwits.com/hpf6637/message/623772356</stembedurl>Another user expressed hopes for further price target increases into the high teens.<stembedurl>https://stocktwits.com/Paul_Volcker/message/623769111</stembedurl>Ardelyx on Monday announced changes to its executive leadership team, including the appointment of Edward Conner as Chief Medical Officer and the exit of CFO Justin Renz. The appointments came on the heels of the company reporting $97.7 million in total revenue, reflecting 33% growth year-over-year, and above an analyst estimate of $81.08 million.Ibsrela, the company’s prescription medicine used in adults to treat irritable bowel syndrome with constipation, generated its highest-ever net sales revenue of $65 million in the quarter. Meanwhile, Xphozah, a prescription medicine used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy, brought in $25 million in the quarter.The company also raised its Ibsrela net sales revenue expectations to $250 million to $260 million for the full year 2025. Net loss per share came in at $0.08, compared to a loss of $0.07 per share reported in the corresponding quarter of 2024, but below a loss per share of $0.14 expected by analysts.Multiple analysts subsequently hiked their price target on the stock on Tuesday morning. Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares. The firm noted that Ardelyx posted a solid performance in Q2, driven by Ibsrela strength.Raymond James, meanwhile, raised the firm's price target on Ardelyx to $12 from $11 and kept an ‘Outperform’ rating on the shares. ARDX stock is up by 1% this year but down by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholders-reportedly-sue-ev-giant-ceo-elon-musk-over-robotaxi-claims/chrLMCtRd21">Tesla Shareholders Reportedly Sue EV Giant, CEO Elon Musk Over Robotaxi Claims: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.

Equity

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.


Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of +38.46% and +15.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Ardelyx, Inc. (ARDX) traded 22% lower on Friday afternoon after Citi lowered its price target on the stock following its recent first-quarter earnings report.Citi reduced its price target on Ardelyx to $10 from $11 while keeping a ‘Buy’ rating. The new price target, however, represents an 83% upside to the stock’s closing price on Thursday.Raymond James also downgraded Ardelyx to ‘Outperform’ from ‘Strong Buy’, and slashed its price target to $11 from $13.The firm said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises.Despite the downgrade, Raymond James remains bullish on Ardelyx, citing its strong execution track record.Ardelyx <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-first-quarter-2025-financial-results-and">reported</a> Q1 total revenue of $74.1 million on Thursday, marking &nbsp;61% growth year-over-year and reflecting increased net product sales and licensing revenue. However, as per Finchat data, this was below an analyst estimate of $79.44 million.U.S. net product sales revenue of Ibsrela, the company’s prescription medication for treating Irritable Bowel Syndrome with Constipation, was $44.4 million, compared to $28.4 million during the same period of 2024.The U.S. net product sales revenue of Xphozah, used as an add-on therapy to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $23.4 million, compared to $15.2 million during the same period in 2024.Net loss per share for the quarter was $0.17, compared to a loss of $0.11 per share in the same quarter of 2024, and broader than an estimated loss of $0.07.On Stocktwits, retail sentiment around ARDX remained in the ‘extremely bullish’ territory over the past 24 hours while message volume rose to ‘extremely high’ from ‘high’.<figure class="image"><img style="aspect-ratio:626/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_02_at_1_56_59_PM_png_99a9fe03a2.webp" alt="ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits" width="626" height="59"><figcaption>ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> is down by over 17% this year and nearly 38% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-core-brand-group-operating-profit-drops-q1/chLUkWFRb0z">Volkswagen Core Brand Group Operating Profit Drops In Q1: But Retail’s Not Rattled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ardelyx Stock Gets Multiple Price Target Cuts After Disappointing Q1 Earnings: But Retail’s Optimistic

Raymond James said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises. 

Shares of biopharma company Ardelyx, Inc. (ARDX) edged up about 0.5% in after-hours trading on Thursday after closing lower during the regular session as investors processed its quarterly earnings and drug sales projections.Ardelyx swung to a fourth-quarter (Q4) net income of $0.02 per diluted share from a loss of $0.12 a year earlier, surpassing analyst expectations of breakeven.&nbsp;Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.Total revenue for the year ended Dec. 31, 2024, was $333.6 million, compared to $124.5 million a year earlier.Ibsrela, its treatment for irritable bowel syndrome with constipation, generated $53.8 million in Q4 net product sales revenue, reflecting about 32% growth from Q3.&nbsp;Full-year 2024 sales reached $158.3 million, and the company expects U.S. net product sales for 2025 to range between $240 million and $250 million.&nbsp;Ardelyx projects Ibsrela to achieve over 10% market share at peak and exceed $1 billion in annual U.S. revenue before its patent expires in 2029.Xphozah, used to manage serum phosphorus levels in adults with chronic kidney disease on dialysis, recorded $57.2 million in Q4 net product sales.In 2024, Xphozah's first full year of commercialization saw U.S. sales hit $160.9 million. The company estimates that peak annual U.S. sales will reach $750 million before its patent expires.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARDX_sentiment_and_message_volume_Feb_20_c5531a04cb.png" alt="ARDX sentiment and message volume Feb 20.png">On Stocktwits, sentiment for ARDX surged deeper into the 'extremely bullish' zone, with message volume spiking 240% in 24 hours.&nbsp;One user highlighted IBSRELA's trajectory toward blockbuster drug status, while another reinforced faith in the company's fundamentals.<stembedurl>https://stocktwits.com/Food4Thought/message/605066169</stembedurl><stembedurl>https://stocktwits.com/Newtothis321/message/604963175</stembedurl>Ardelyx ended 2024 with $250.1 million in cash, cash equivalents, and short-term investments, up from $184.3 million a year earlier.&nbsp;The stock has gained over 13% year-to-date, though short interest has increased from 10% at the start of 2025 to about 11.2% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

Ardelyx Beats Q3 Sales Estimates, Shares Climb

Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report:
read more...

Ardelyx's Earnings Outlook

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (Ardelyx or the Company) (NASDAQ: ARDX) and reminds investors of the October 15...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$5.96
Prev Close	$6.15
Open	$6.13
Dividend Yield	0.00%
50-Day Moving Average	$5.62
Beta	1.06
Avg. Volume	4.45M
PE Ratio	-26.03

52-Week High	$7.18
52-Week Low	$3.21
Market Capitalization	$1.48B
EPS (Annual)	-$0.1664
Price to Book	10.61
Revenue Per Employee	$844,594.94
Enterprise Value/EBITDA	N/A

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARDX News

ARDX Ardelyx Inc